Abstract: The current disclosure provides for novel therapeutic methods by identifying glioblastoma patient populations that may be treated effectively by immunotherapies. Also provided are therapies that may be used in combination of immune checkpoint therapy (ICB) to increase the effectiveness of the therapy. Aspects of the disclosure relate to a method of treating glioblastoma in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after the subject has been determined to have low expression of CD73 in a biological sample from the subject.

Abstract: Aspects of the disclosure relate to a method of treating glioblastoma in a subject comprising administering to the subject a KDM6B inhibitor. In some aspects, the methods are performed in combination with an immunoterhapy. Further aspects relate to a composition comprising a KDM6B inhibitor and an immunotherapy.

Abstract: The current disclosure provides for novel therapeutic methods by identifying cancer patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after the subject has been determined to have increased expression of CXCL13 in a biological sample from the subject.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Provided herein are methods of treating cancer comprising administering an EZH2 inhibitor which may be combined with an immune checkpoint inhibitor. Further provided herein are methods of depleting regulatory T cells (Tregs) in a subject comprising administering an EZH2 inhibitor to the subject. Also provided herein are pharmaceutical compositions comprising CPI-1205 and an immune checkpoint inhibitor.

Abstract: A system, method, and computer-readable medium to deliver patient reported outcomes and therapeutic recommendations to patients with immunotherapy. Management of adverse events in the treatment of patients implementing a digital therapeutic(s) that enforces a digital care pathway that receives patient data of answers to machine generated questions and patient symptoms, where the patient data is consumed by digital care pathway. The patient data is process with digital therapeutics (DTx) knowledge models that influence the digital care pathway. Recommendations are provided based on the processed data.

Abstract: Provided herein are methods for identifying a subject as a responder or non-responder to immune checkpoint blockade by detecting a B cell signature. Further provided herein are methods for treating cancer by administering immune checkpoint blockade therapy to a subject identified to have a B cell signature.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors.